$GRTX
Galera Therapeutics, Inc.

2022 Q4 Form 10-Q Financial Statement

#000095017022023516 Filed on November 09, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.021M $4.853M $5.487M
YoY Change -4.98% -11.55% 38.91%
% of Gross Profit
Research & Development $8.137M $8.106M $14.81M
YoY Change -11.69% -45.28% 22.09%
% of Gross Profit
Depreciation & Amortization $26.00K $27.00K $106.0K
YoY Change -94.4% -74.53% 17.78%
% of Gross Profit
Operating Expenses $13.16M $8.106M $14.81M
YoY Change -9.24% -45.28% 22.09%
Operating Profit -$12.96M -$20.30M
YoY Change -36.16% 26.26%
Interest Expense -$3.073M $3.245M $2.327M
YoY Change 33.09% 39.45% 88.42%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$16.26M -$16.03M -$22.63M
YoY Change -3.27% -29.14% 32.47%
Income Tax -$70.00K
% Of Pretax Income
Net Earnings -$16.19M -$16.03M -$22.63M
YoY Change -3.68% -29.14% 32.49%
Net Earnings / Revenue
Basic Earnings Per Share -$0.60 -$0.86
Diluted Earnings Per Share -$0.58 -$0.60 -$860.1K
COMMON SHARES
Basic Shares Outstanding 28.50M 26.82M 26.30M
Diluted Shares Outstanding 26.82M 26.30M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $31.60M $42.77M $88.71M
YoY Change -55.63% -51.79% -0.55%
Cash & Equivalents $4.266M $12.73M $17.63M
Short-Term Investments $27.33M $30.04M $71.07M
Other Short-Term Assets $6.938M $2.148M $3.983M
YoY Change 12.36% -46.07% 24.47%
Inventory
Prepaid Expenses $1.359M
Receivables
Other Receivables
Total Short-Term Assets $38.54M $44.92M $92.69M
YoY Change -50.21% -51.54% 0.42%
LONG-TERM ASSETS
Property, Plant & Equipment $438.0K $464.0K $938.0K
YoY Change -16.89% -50.53% -12.58%
Goodwill $881.0K $881.0K $881.0K
YoY Change 0.0% 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.881M $2.087M $1.626M
YoY Change -3.88% 28.35% 70.08%
Total Long-Term Assets $5.501M $5.796M $6.077M
YoY Change -7.06% -4.62% 5.3%
TOTAL ASSETS
Total Short-Term Assets $38.54M $44.92M $92.69M
Total Long-Term Assets $5.501M $5.796M $6.077M
Total Assets $44.04M $50.71M $98.77M
YoY Change -47.14% -48.65% 0.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.581M $3.591M $7.181M
YoY Change -29.0% -49.99% 78.94%
Accrued Expenses $9.754M $7.932M $8.272M
YoY Change 27.79% -4.11% 32.56%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $13.38M $11.63M $15.72M
YoY Change 3.43% -26.02% 49.75%
LONG-TERM LIABILITIES
Long-Term Debt $139.6M $136.3M $125.8M
YoY Change 9.04% 8.4% 102.5%
Other Long-Term Liabilities $0.00 $0.00 $184.0K
YoY Change -100.0% -100.0% -63.2%
Total Long-Term Liabilities $139.6M $136.3M $125.9M
YoY Change 9.0% 8.24% 101.17%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.38M $11.63M $15.72M
Total Long-Term Liabilities $139.6M $136.3M $125.9M
Total Liabilities $153.2M $148.2M $141.9M
YoY Change 8.42% 4.43% 93.37%
SHAREHOLDERS EQUITY
Retained Earnings -$378.3M -$362.1M -$299.3M
YoY Change 19.68% 20.98% 38.89%
Common Stock $269.2M $264.7M $256.1M
YoY Change 4.28% 3.36% 6.69%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$109.2M -$97.50M -$43.17M
YoY Change
Total Liabilities & Shareholders Equity $44.04M $50.71M $98.77M
YoY Change -47.14% -48.65% 0.7%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$16.19M -$16.03M -$22.63M
YoY Change -3.68% -29.14% 32.49%
Depreciation, Depletion And Amortization $26.00K $27.00K $106.0K
YoY Change -94.4% -74.53% 17.78%
Cash From Operating Activities -$13.95M -$9.210M -$18.40M
YoY Change -20.07% -49.96% 20.37%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$5.000K -$25.00K
YoY Change -100.0% -80.0%
Acquisitions
YoY Change
Other Investing Activities $2.779M $4.609M -$43.02M
YoY Change -85.9% -110.71% -398.51%
Cash From Investing Activities $2.779M $4.604M -$43.04M
YoY Change -85.86% -110.7% -398.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.702M 10.00K 40.61M
YoY Change 12181.82% -99.98% 18360.0%
NET CHANGE
Cash From Operating Activities -13.95M -9.210M -18.40M
Cash From Investing Activities 2.779M 4.604M -43.04M
Cash From Financing Activities 2.702M 10.00K 40.61M
Net Change In Cash -8.464M -4.596M -20.83M
YoY Change -480.06% -77.94% 3056.52%
FREE CASH FLOW
Cash From Operating Activities -$13.95M -$9.210M -$18.40M
Capital Expenditures $0.00 -$5.000K -$25.00K
Free Cash Flow -$13.95M -$9.205M -$18.38M
YoY Change -19.82% -49.92% 20.2%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001563577
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39114
dei Entity Registrant Name
EntityRegistrantName
Galera Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-1454898
dei Entity Address Address Line1
EntityAddressAddressLine1
2 W. Liberty Blvd #100
dei Entity Address City Or Town
EntityAddressCityOrTown
Malvern
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19355
dei City Area Code
CityAreaCode
610
dei Local Phone Number
LocalPhoneNumber
725-1500
dei Security12b Title
Security12bTitle
Common Stock,$0.001 par value per share
dei Trading Symbol
TradingSymbol
GRTX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
28500066
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12730000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19859000
CY2022Q3 us-gaap Short Term Investments
ShortTermInvestments
30039000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
51358000
CY2022Q3 us-gaap Restricted Cash
RestrictedCash
50000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
0
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2098000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6175000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
44917000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
77392000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
464000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
527000
CY2022Q3 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
2258000
CY2021Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
2258000
CY2022Q3 us-gaap Goodwill
Goodwill
881000
CY2021Q4 us-gaap Goodwill
Goodwill
881000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
106000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
296000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2087000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1957000
CY2022Q3 us-gaap Assets
Assets
50713000
CY2021Q4 us-gaap Assets
Assets
83311000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3591000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5044000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7932000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7633000
CY2022Q3 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
109000
CY2021Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
258000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
11632000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12935000
CY2022Q3 us-gaap Royalty Guarantees Commitments Amount
RoyaltyGuaranteesCommitmentsAmount
136310000
CY2021Q4 us-gaap Royalty Guarantees Commitments Amount
RoyaltyGuaranteesCommitmentsAmount
128063000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
44000
CY2022Q3 us-gaap Deferred Tax Liabilities Derivatives
DeferredTaxLiabilitiesDerivatives
273000
CY2021Q4 us-gaap Deferred Tax Liabilities Derivatives
DeferredTaxLiabilitiesDerivatives
273000
CY2022Q3 us-gaap Liabilities
Liabilities
148215000
CY2021Q4 us-gaap Liabilities
Liabilities
141315000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
0
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26831589
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26831589
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26458767
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26458767
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
27000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
26000
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
264700000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
258086000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-93000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-14000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-362136000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-316102000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-97502000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-58004000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
50713000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
83311000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8106000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14813000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22875000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
43203000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4853000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5487000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15193000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15667000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12959000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-20300000
us-gaap Operating Income Loss
OperatingIncomeLoss
-38068000
us-gaap Operating Income Loss
OperatingIncomeLoss
-58870000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
171000
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
3000
us-gaap Investment Income Interest
InvestmentIncomeInterest
256000
us-gaap Investment Income Interest
InvestmentIncomeInterest
28000
CY2022Q3 us-gaap Interest Expense
InterestExpense
3245000
CY2021Q3 us-gaap Interest Expense
InterestExpense
2327000
us-gaap Interest Expense
InterestExpense
8247000
us-gaap Interest Expense
InterestExpense
4882000
CY2022Q3 grtx Gain On Disposal Of Assets
GainOnDisposalOfAssets
1000
CY2021Q3 grtx Gain On Disposal Of Assets
GainOnDisposalOfAssets
0
grtx Gain On Disposal Of Assets
GainOnDisposalOfAssets
27000
grtx Gain On Disposal Of Assets
GainOnDisposalOfAssets
0
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-3000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-16033000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-22626000
us-gaap Net Income Loss
NetIncomeLoss
-46034000
us-gaap Net Income Loss
NetIncomeLoss
-63727000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.60
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.60
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.86
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.86
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.72
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.72
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.49
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.49
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26823546
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26823546
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26304920
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26304920
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26798348
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26798348
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25569545
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25569545
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-16033000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-22626000
us-gaap Net Income Loss
NetIncomeLoss
-46034000
us-gaap Net Income Loss
NetIncomeLoss
-63727000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
17000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-5000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-79000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-14000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16016000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22631000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-46113000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-63741000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-58004000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1848000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
58000
CY2022Q1 grtx Sale Of Shares Under Open Market Sale Agrrement
SaleOfSharesUnderOpenMarketSaleAgrrement
-1117000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-47000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-15443000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-70471000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1830000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-49000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-14558000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-83246000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1750000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
17000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-16033000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-97502000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
6118000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1791000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
235000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-18715000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-10573000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1611000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
120000
CY2021Q2 grtx Sale Of Shares Under Open Market Sale Agrrement
SaleOfSharesUnderOpenMarketSaleAgrrement
-5718000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-7000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-22386000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-25517000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1870000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
890000
CY2021Q3 grtx Sale Of Shares Under Open Market Sale Agrrement
SaleOfSharesUnderOpenMarketSaleAgrrement
2221000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-5000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-22626000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-43167000
us-gaap Profit Loss
ProfitLoss
-46034000
us-gaap Profit Loss
ProfitLoss
-63727000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
88000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
314000
us-gaap Paid In Kind Interest
PaidInKindInterest
8247000
us-gaap Paid In Kind Interest
PaidInKindInterest
4882000
us-gaap Share Based Compensation
ShareBasedCompensation
5428000
us-gaap Share Based Compensation
ShareBasedCompensation
5272000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-4077000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1171000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-60000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-7000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1453000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2035000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
299000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-466000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
193000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29481000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-50512000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
46920000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
67183000
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
68160000
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
53000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
25000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
230000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
21215000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-14413000
grtx Proceeds From Royalty Purchase Agreement
ProceedsFromRoyaltyPurchaseAgreement
0
grtx Proceeds From Royalty Purchase Agreement
ProceedsFromRoyaltyPurchaseAgreement
57500000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
1117000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
7939000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
70000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1246000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1187000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
66685000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7079000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1760000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19859000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15872000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12780000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17632000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
7000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2012-11-19
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-362100000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
110000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
109000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of unaudited interim consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the unaudited interim consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the unaudited interim consolidated financial statements in the period they are determined to be necessary. Significant areas that require management’s estimates include share-based compensation assumptions, royalty purchase liability assumptions and accrued research and development expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5333390
CY2022Q3 us-gaap Restricted Cash
RestrictedCash
50000
grtx Increase Decrease In Research And Development Expense
IncreaseDecreaseInResearchAndDevelopmentExpense
300000
grtx Funding Available Under The Grant
FundingAvailableUnderTheGrant
1100000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6557618
us-gaap Fair Value Liabilities Measured On Recurring Basis Debt Instrument Valuation Techniques Change In Technique Quantification Of Effect
FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect
0
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2140000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2114000
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1676000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1587000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
464000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
527000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
100000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
300000
CY2022Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2121000
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2038000
CY2022Q3 grtx Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
5448000
CY2021Q4 grtx Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
5360000
CY2022Q3 grtx Accrued Professional Fees And Other Expenses Current
AccruedProfessionalFeesAndOtherExpensesCurrent
363000
CY2021Q4 grtx Accrued Professional Fees And Other Expenses Current
AccruedProfessionalFeesAndOtherExpensesCurrent
235000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7932000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7633000
CY2022Q3 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P6Y
CY2022Q3 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
4700000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
106000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
296000
CY2022Q3 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
109000
CY2021Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
258000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
44000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
109000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
302000
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
63000
CY2021Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
76000
us-gaap Operating Lease Expense
OperatingLeaseExpense
193000
us-gaap Operating Lease Expense
OperatingLeaseExpense
225000
CY2022Q3 grtx Operating Lease Interest Expense
OperatingLeaseInterestExpense
2000
CY2021Q3 grtx Operating Lease Interest Expense
OperatingLeaseInterestExpense
5000
grtx Operating Lease Interest Expense
OperatingLeaseInterestExpense
8000
grtx Operating Lease Interest Expense
OperatingLeaseInterestExpense
18000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
65000
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
81000
us-gaap Operating Lease Cost
OperatingLeaseCost
201000
us-gaap Operating Lease Cost
OperatingLeaseCost
243000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
58526
us-gaap Operating Lease Payments
OperatingLeasePayments
200000
us-gaap Operating Lease Payments
OperatingLeasePayments
245000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
70000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
66000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
44000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1750000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1870000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5428000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5272000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4970975
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.45
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1604146
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.05
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.22
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
509638
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
8.93
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6006957
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.77
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M12D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3339327
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.15
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y10M24D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
6006957
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
6.77
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y2M12D
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
11900000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y3M18D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
300000
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
100000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.57
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.26
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y2M12D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y2M12D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.927
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.904
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0206
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0069
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0

Files In Submission

Name View Source Status
grtx-20220930_htm.xml Edgar Link completed
0000950170-22-023516-index-headers.html Edgar Link pending
0000950170-22-023516-index.html Edgar Link pending
0000950170-22-023516.txt Edgar Link pending
0000950170-22-023516-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
grtx-20220930.htm Edgar Link pending
grtx-20220930.xsd Edgar Link pending
grtx-ex10_1.htm Edgar Link pending
grtx-20220930_lab.xml Edgar Link unprocessable
grtx-20220930_def.xml Edgar Link unprocessable
grtx-ex10_2.htm Edgar Link pending
grtx-ex31_1.htm Edgar Link pending
grtx-ex31_2.htm Edgar Link pending
grtx-ex32_1.htm Edgar Link pending
grtx-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
grtx-20220930_cal.xml Edgar Link unprocessable
grtx-20220930_pre.xml Edgar Link unprocessable